Published in Am J Pathol on April 01, 1999
Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ (2000) 4.21
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut (2008) 2.51
The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology (2009) 2.35
Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer (2001) 2.26
Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell (2012) 2.16
History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology (2010) 2.05
Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 1.84
Body mass index and Barrett's oesophagus in women. Gut (2009) 1.70
Biomarkers in gastrointestinal cancers. Am J Gastroenterol (2008) 1.45
Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut (2003) 1.32
Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg (2003) 1.23
Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut (2005) 1.18
MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer (2011) 1.17
ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res (2008) 1.17
Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res (2008) 1.15
Stress and the epigenetic landscape: a link to the pathobiology of human diseases? Nat Rev Genet (2010) 1.13
Metabolic syndrome and gastrointestinal diseases. J Gastroenterol (2007) 1.12
Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer (2001) 1.09
Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res (2012) 1.07
Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol (2005) 1.06
Gastro-oesophageal cancer: death at the junction. BMJ (2000) 1.06
Diagnosis and management of Barrett's oesophagus. BMJ (2010) 1.04
MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol (2009) 1.02
Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia (2007) 1.01
Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci (2004) 1.01
Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol (2001) 1.00
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer (2002) 0.99
How to make a Barrett esophagus: pathophysiology of columnar metaplasia of the esophagus. Dig Dis Sci (2005) 0.98
Raman spectroscopy: elucidation of biochemical changes in carcinogenesis of oesophagus. Br J Cancer (2006) 0.98
Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway. Biochem J (2004) 0.97
The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. J Clin Pathol (2004) 0.97
Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions. Am J Pathol (2001) 0.95
Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut (2003) 0.93
Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol (2012) 0.92
Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression. J Gastroenterol (2013) 0.92
Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma. World J Gastroenterol (2006) 0.92
Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Br J Cancer (2007) 0.91
Barrett esophagus: what a mouse model can teach us about human disease. Cell Cycle (2012) 0.90
Proliferative activity in Barrett's esophagus before and after antireflux surgery. Ann Surg (2001) 0.89
Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. Cancer Lett (2008) 0.89
Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. J Clin Pathol (2010) 0.88
Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas. Cancer (2010) 0.88
Protagonist: endoscopic surveillance of patients with Barrett's oesophagus. Gut (2002) 0.85
A systematic review and meta-analysis of the treatment for Barrett's esophagus. Dig Dis Sci (2008) 0.85
Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark (2010) 0.83
Intestine in the lung. J Biol (2004) 0.83
Role of Th-2 cytokines in the development of Barrett's esophagus in rats. J Gastroenterol (2011) 0.82
Molecular aspects of esophageal development. Ann N Y Acad Sci (2011) 0.81
Mucin pattern reflects the origin of the adenocarcinoma in Barrett's esophagus: a retrospective clinical and laboratorial study. World J Surg Oncol (2009) 0.81
Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma. J Carcinog (2015) 0.80
Smoking and Barrett's esophagus in women who undergo upper endoscopy. Dig Dis Sci (2011) 0.80
Multilayered epithelium may be found in patients with Barrett's epithelium and dysplasia or adenocarcinoma. Dig Dis Sci (2006) 0.80
Meta-analysis of Barrett's esophagus in China. World J Gastroenterol (2013) 0.79
The resistance of esophageal adenocarcinoma to bile salt insult is associated with manganese superoxide dismutase expression. J Surg Res (2010) 0.79
Assessment of mutational load in biopsy tissue provides additional information about genomic instability to histological classifications of Barrett's esophagus. J Gastrointest Cancer (2014) 0.79
Bile acids but not acidic acids induce Barrett's esophagus. Int J Clin Exp Pathol (2015) 0.79
Barrett's esophagus: environmental influences in the progression of dysplasia. World J Surg (2003) 0.79
Rebamipide Alters the Esophageal Microbiome and Reduces the Incidence of Barrett's Esophagus in a Rat Model. Dig Dis Sci (2015) 0.79
Barrett's Esophagus: Emerging Knowledge and Management Strategies. Patholog Res Int (2012) 0.78
Molecular changes in the progression of Barrett's oesophagus. Postgrad Med J (2007) 0.78
Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology. Br J Cancer (2003) 0.78
The Nissen fundoplication: indication, technical aspects and postoperative outcome. Langenbecks Arch Surg (2004) 0.78
Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full! Gut (2006) 0.77
Immunohistochemical/histochemical double staining method in the study of the columnar metaplasia of the oesophagus. Eur J Histochem (2014) 0.77
The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis. Br J Cancer (2004) 0.77
Evaluation of fatty acid synthase expression in oesophageal mucosa of patients with oesophagitis, Barrett's oesophagus and adenocarcinoma. J Cancer Res Clin Oncol (2009) 0.77
Changes in screening, prognosis and therapy for esophageal adenocarcinoma in Barrett's esophagus. Curr Opin Gastroenterol (2009) 0.76
Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma. J Gastroenterol (2015) 0.76
Microsatellite alterations in phenotypically normal esophageal squamous epithelium and metaplasia-dysplasia-adenocarcinoma sequence. World J Gastroenterol (2008) 0.76
Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis. BMC Cancer (2014) 0.76
Surveillance for Barrett's oesophagus. The conundrum of Barrett's oesophagus is changing. BMJ (2001) 0.76
Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel. Genes Cancer (2015) 0.76
Synthesis and characterization of anti-EGFR fluorescent nanoparticles for optical molecular imaging. Bioconjug Chem (2013) 0.76
Ki-67 Antigen Overexpression Is Associated with the Metaplasia-Adenocarcinoma Sequence in Barrett's Esophagus. Gastroenterol Res Pract (2012) 0.76
Management of Barrett's oesophagus and intramucosal oesophageal cancer: a review of recent development. Therap Adv Gastroenterol (2012) 0.76
Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Curr Oncol (2006) 0.75
Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence. BMC Cancer (2016) 0.75
Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples. BMC Res Notes (2017) 0.75
Early onset esophageal adenocarcinoma: a distinct molecular entity? Oncoscience (2016) 0.75
Cell adhesion molecules. Sticky moments in the clinic. BMJ (1999) 0.75
Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1. Diagn Pathol (2016) 0.75
Metallothionein in human oesophagus, Barrett's epithelium and adenocarcinoma. Br J Cancer (2002) 0.75
Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas. Sci Rep (2017) 0.75
Low grade dysplasia in Barrett's esophagus: Should we worry? World J Gastrointest Pathophysiol (2014) 0.75
Hereditary Factors in Esophageal Adenocarcinoma. Gastrointest Tumors (2014) 0.75
Transcriptional regulation by normal epithelium of premalignant to malignant progression in Barrett's esophagus. Sci Rep (2016) 0.75
Surveillance for gastrointestinal malignancies. World J Gastroenterol (2012) 0.75
Endoscopic water jets used to ablate Barrett's esophagus: preliminary results of a new technique. Surg Endosc (2008) 0.75
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA (1991) 11.53
Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet (1998) 10.51
An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology (1993) 5.41
Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology (1992) 3.86
Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with beta-catenin. Mol Cell Biol (1998) 3.79
Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology (1987) 3.56
The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology (1996) 3.11
Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst (1995) 2.83
Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology (1992) 2.57
17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A (1996) 2.53
Prevalence of metaplasia at the gastro-oesophageal junction. Lancet (1994) 2.45
Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet (1996) 2.33
Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science (1996) 2.22
Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg (1995) 2.17
The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev (1992) 2.05
Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology (1995) 2.02
Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology (1993) 2.00
Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg (1993) 2.00
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res (1998) 1.94
Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev (1997) 1.88
Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer (1996) 1.82
p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res (1997) 1.67
Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res (1992) 1.65
A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol (1994) 1.59
Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet (1997) 1.57
Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A (1992) 1.56
17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res (1994) 1.52
TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology (1994) 1.50
Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol (1998) 1.49
Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res (1994) 1.49
p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res (1991) 1.48
Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene (1996) 1.46
p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology (1994) 1.43
Distribution of cytokeratin markers in Barrett's specialized columnar epithelium. Gastroenterology (1997) 1.41
The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol (1996) 1.40
Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci U S A (1993) 1.40
Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev (1996) 1.39
Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol (1998) 1.36
Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut (1992) 1.31
High-grade dysplasia in the columnar-lined esophagus. Am J Surg (1991) 1.29
p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology (1993) 1.21
The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc (1996) 1.19
Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer (1998) 1.18
Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases. Am J Surg Pathol (1995) 1.17
In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer (1998) 1.15
APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology (1994) 1.14
Mucosa-associated lymphoid tissue (MALT) in Barrett's esophagus: prospective evaluation and association with gastric MALT, MALT lymphoma, and Helicobacter pylori. Am J Gastroenterol (1997) 1.14
Mechanisms of acid injury to rabbit esophageal epithelium. Role of basolateral cell membrane acidification. Gastroenterology (1991) 1.11
Regression and progression of Barrett's oesophagus after antireflux surgery. Br J Surg (1995) 1.09
Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett's-associated esophageal adenocarcinoma. Cancer Res (1996) 1.07
Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res (1996) 1.06
Allelotype study of esophageal carcinoma. Genes Chromosomes Cancer (1994) 1.03
Expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in Barrett's metaplasia and the native oesophageal epithelium: delineation of epithelial phenotype. J Pathol (1994) 1.02
Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg (1997) 1.02
Assessment of combined bile acid and pH profiles using an automated sampling device in gastro-oesophageal reflux disease. Br J Surg (1998) 0.98
Persistent clonal areas and clonal expansion in Barrett's esophagus. Cancer Res (1992) 0.97
Significance of intestinal metaplasia in different areas of esophagus including esophagogastric junction. Dig Dis Sci (1997) 0.97
Loss of transforming growth factor-beta type II receptor gene expression in primary human esophageal cancer. Lab Invest (1996) 0.97
Detection of a shared colon epithelial epitope on Barrett epithelium by a novel monoclonal antibody. Ann Intern Med (1994) 0.96
Epithelial stem cells in gastrointestinal morphogenesis, adaptation and carcinogenesis. Semin Cell Biol (1992) 0.92
Is Barrett's esophagus associated with intestinal metaplasia of the gastric cardia? Am J Gastroenterol (1997) 0.90
Sucrase-isomaltase gene expression in Barrett's esophagus and adenocarcinoma. Gastroenterology (1993) 0.89
Deficient transforming growth factor-beta1 activation and excessive insulin-like growth factor II (IGFII) expression in IGFII receptor-mutant tumors. Cancer Res (1997) 0.89
Oesophageal cancer in France and Switzerland: recent time trends. Eur J Cancer Prev (1992) 0.85
High-grade dysplasia in Barrett's oesophagus. Br J Surg (1997) 0.84
Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: biological and clinical variables. Int J Cancer (1995) 0.82
Barrett's esophagus. Semin Oncol (1994) 0.82
Scanning electron microscopy of the human esophagus: application to Barrett's esophagus, a precancerous lesion. Microsc Res Tech (1995) 0.81
bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence. Mod Pathol (1995) 0.81
Gastritis in Barrett's esophagus. World J Surg (1995) 0.80
Clonality of esophageal carcinomas: genetic and epigenetic events leading to loss of genomic stability. Dis Esophagus (1997) 0.78
Metabolic competence and susceptibility of intestinal epithelium to genotoxic injury during regeneration. Carcinogenesis (1997) 0.78
EXPERIMENTAL PNEUMONIA BY INTRABRONCHIAL INSUFFLATION. J Exp Med (1912) 31.80
The Vienna classification of gastrointestinal epithelial neoplasia. Gut (2000) 9.39
EXPERIMENTAL BRONCHOPNEUMONIA BY INTRABRONCHIAL INSUFFLATION. J Exp Med (1912) 8.95
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet (2001) 7.31
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challenges. Am J Bioeth (2009) 6.13
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Predictability of the postoperative course of Crohn's disease. Gastroenterology (1990) 5.30
PNEUMONIC LESIONS MADE BY INTRABRONCHIAL INSUFFLATION OF NON-VIRULENT PNEUMOCOCCI. J Exp Med (1913) 5.14
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
Colorectal cancer. Lancet (1999) 4.72
Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex. Rev Infect Dis (1987) 4.54
Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol (1988) 4.47
Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med (1978) 4.15
Waiting times for cancer patients in England after general practitioners' referrals: retrospective national survey. BMJ (2000) 4.13
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother (1977) 3.91
Aspergillosis complicating neoplastic disease. Am J Med (1973) 3.80
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 3.57
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology (1995) 3.44
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis (1972) 3.28
Hepatocytes from non-hepatic adult stem cells. Nature (2000) 3.27
The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol (1990) 3.23
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother (1987) 3.06
Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol (2001) 3.04
Hemagglutination typing of Escherichia coli: definition of seven hemagglutination types. J Clin Microbiol (1980) 3.03
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
EXPERIMENTAL CONTRIBUTION TO THE STUDY OF THE PATH BY WHICH FLUIDS ARE CARRIED FROM THE PERITONEAL CAVITY INTO THE CIRULATION. J Exp Med (1896) 2.94
Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother (1973) 2.85
Hemolysin and K antigens in relation to serotype and hemagglutination type of Escherichia coli isolated from extraintestinal infections. J Clin Microbiol (1981) 2.82
In vitro studies of piperacilin, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.82
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
Yersinia enteritis and enterocolitis: gastroenterological aspects. Gastroenterology (1977) 2.79
Non-alcoholic duct destructive chronic pancreatitis. Gut (1997) 2.79
T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol (1997) 2.76
TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut (2011) 2.75
Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med (1993) 2.74
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Appendectomy protects against ulcerative colitis. Gastroenterology (1994) 2.71
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol (1991) 2.71
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut (1984) 2.70
6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med (1989) 2.70
Microscopic colitis with giant cells. Histopathology (2002) 2.64
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Epstein-Barr virus persistence and virus-associated tumours. Lancet (1994) 2.60
Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl Microbiol (1971) 2.60
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis (1986) 2.56
Nontuberculous mycobacterial infections: a clinical review. Infection (2004) 2.56
Septicemia due to Aeromonas hydrophila: clinical and immunologic aspects. J Infect Dis (1973) 2.55
Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology (1987) 2.54
THE REACTION OF THE LUNGS TO THE INTRABRONCHIAL INSUFFLATION OF KILLED VIRULENT PNEUMOCOCCI AND OF PLAIN STERILE BOUILLON. J Exp Med (1913) 2.53
Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut (2008) 2.51
Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest (1979) 2.50
Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology (1999) 2.46
Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology (1999) 2.46
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med (1990) 2.45
PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet (1997) 2.44
Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia. J Lab Clin Med (1975) 2.41
Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med (1982) 2.34
Radioimmunoassay, acetylating radio-enzymatic assay, and microbioassay of gentamicin: a comparative study. J Lab Clin Med (1975) 2.30
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
Nocardia asteroides infection complicating neoplastic disease. Am J Med (1971) 2.23
Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli. Antimicrob Agents Chemother (1980) 2.23
Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene (1998) 2.22
Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet (1990) 2.22
Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science (1996) 2.22
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
Human papillomavirus DNA sequences in esophagus squamous cell carcinoma. Gastroenterology (1994) 2.20
A short 5' flanking region containing conserved sequences is required for silkworm alanine tRNA gene activity. Proc Natl Acad Sci U S A (1983) 2.19
Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet (1996) 2.19
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology (1997) 2.18
Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem (1999) 2.17
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Piperacillin therapy for serious bacterial infections. Am J Med (1980) 2.14
Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med (1980) 2.11
A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med (1972) 2.11
Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest (1999) 2.10
PNEUMONIC LESIONS CAUSED BY BACILLUS MEGATHERIUM. J Exp Med (1913) 2.10
Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res (1999) 2.09
A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE). Health Technol Assess (2009) 2.09
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst (2000) 2.05
Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology (1999) 2.04
Experimentally induced hypoglycaemia. Lancet (1996) 2.02
The future of general medicine. J R Coll Physicians Lond (1998) 2.02
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J Clin Pathol (1999) 1.98
Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl (1999) 1.97
Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins. Infect Immun (1991) 1.97
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res (1998) 1.94